Clinical Trials Logo

CD clinical trials

View clinical trials related to CD.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03487900 Active, not recruiting - CD Clinical Trials

Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up

CREDO2
Start date: March 13, 2018
Phase: N/A
Study type: Interventional

The CREDO 2 study follows CREDO 1 study, which aims to construct an objective evaluation of endoscopic remission in Crohn's Disease (CD). In addition to reproducibility and validation, the predictive value of this remission evaluation needs to be tested in different settings to valorise its usefulness in clinical practice and in clinical trials. CREDO 2 aims to investigate whether the evaluation of endoscopic remission, as defined in CREDO 1, in patients in clinical remission is predictive of sustained clinical remission at 2 years. The design of CREDO2 is a multicentre longitudinal prospective cohort study. The screening period to include a patient is two weeks. Patients will be followed up to week 104.

NCT ID: NCT03306446 Active, not recruiting - CD Clinical Trials

Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab

CURE
Start date: March 17, 2015
Phase: Phase 4
Study type: Interventional

This is a prospective, longitudinal, multicenter study conducted in a cohort of patients with early CD. This study will not change the patient/physician relationship.

NCT ID: NCT01757964 Active, not recruiting - Ulcerative Colitis Clinical Trials

Bacteriotherapy in Pediatric Inflammatory Bowel Disease

Start date: December 2012
Phase: Phase 1
Study type: Interventional

In this study, the investigators want to see if Bacteriotherapy (also referred to as stool transplantation) improves the symptoms and decreases inflammation in children with Inflammatory Bowel Disease (IBD). Examples of IBD are Crohn's Disease and Ulcerative Colitis. Additionally, researchers want to learn whether this experimental therapy delays the need for starting additional medications to treat pediatric IBD.